A Phase 3, Multicenter, Open-Label Extension Trial Of Oral RPC1063 As Therapy For Moderate To Severe Ulcerative Colitis
Principal Investigator(s)
Email for information
Funded by
Geneva
Research Start Date
Status
Active
This is an open-label, multicenter, extension trial to evaluate the long term safety and efficacy of RPC1063 in patients with moderately to severely active ulcerative colitis (UC). Patients who have previously participated in a trial of RPC1063 for UC will be eligible for entry in this trial if they meet the eligibility criterion for participation as outlined in the prior trial.
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.